Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Published: November 2020

No. of Pages: 88

Price:

Single User License: US $ 5500 US $ 4125
Corporate User License: US $ 9504 US $ 7128

Report Description
Table of Contents

Report Scope:

The scope of this study encompasses the global and regional markets for Alzheimer’s therapeutics and diagnostics. These markets are segmented by branded and generic drugs, and mechanism of action, such as acetylcholine inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, a combination drug of donepezil and memantine, tau aggregation inhibitors (TAI) and amyloid-beta (Aβ) vaccines. Drugs are also segmented by the stage of Alzheimer’s disease they treat, i.e., mild to moderate, severe and prodromal.

BCC Research analyzed each market and its applications, regulatory environment, assistive technologies, market projections and market share. Issues discussed include the major drug profiles, clinical groundwork, technological features and trends. The regional markets for AD therapeutics and diagnostics include selected markets in the U.S., Canada, the U.K., France, Germany, Italy, Spain, Japan, China and India. These markets are grouped as North America, Europe, Asia-Pacific and Rest of the world (RoW).

Report Includes:

- 27 tables

- An overview of the global market for Alzheimer's disease (AD) therapeutics and diagnostics

- Estimation of the market size and analyses of global market trends with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025

- Detailed description of Alzheimer's disease and discussion on disease-related events, etiology and epidemiology covering prevalence and incidence rates

- Identification of diagnostic tools and equipment; evaluation of important scientific and technological frameworks; and coverage of developments in the global market for Alzheimer's disease therapeutics and diagnostics.

- Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease as well as highlights of the promising new drug candidates and diagnostic imaging agents

- Market share analysis of Alzheimer's disease therapeutics and diagnostics, by mechanism of action, disease stage and major geographical regions covering North America, Europe, APAC and Rest of the World

- Detailed analysis of the current market trends, market forecast, drivers, challenges, and opportunities affecting market growth and discussion on regulatory and competitive elements that are affecting the future marketplace

- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies

- Company profiles of major market players, including AbbVie, AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Pfizer Inc., Novartis and Sanofi

Summary:

The global market for Alzheimer’s treatment was valued at REDACTED in 2019. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach slightly over REDACTED by 2025. The increased government funding in neurology research and an ever-growing demand for research focused on drug discovery for development of novel therapies in neurological disorders are driving the growth of the market.

Reasons for Doing this Study:

Alzheimer’s disease cannot be prevented, cured or slowed, and it is a rapidly growing and serious health problem, affecting more than 17 million worldwide. Therapies for AD provide temporary and modest improvements in the well-being of individuals, but none of the approved drugs can modify the course of the disease progression. The immense size of the affected population and lack of appropriate and effective treatment offers a tremendous commercial opportunity for the makers of AD drugs and diagnostics.

The understanding of the underlying reasons and mechanisms involved in AD is very limited. Drug developers have continually failed to demonstrate meaningful clinical benefits of treatment for a myriad of investigational compounds due to stringent regulations. High drug attrition rates and long drug approval times have driven pharmaceutical companies and technology ventures closer to each other for collaborations. Specifically, diagnostic technology companies are rigorously trying to bring about effective biomarker technologies to assist and enhance the drug development process for prospective drug candidates. Regulatory bodies are highly supportive of the use of diagnostic technologies in order

to improve drug attrition rates.

Despite the recurring failures in the development of novel therapies for AD, the global markets are demanding new and more effective disease attenuating treatments, with first-in-class approvals. This expectation and the increasing incidence of AD associated with the aging population are driving the market.

Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
Alzheimer's Disease: Definition and Market Structure
Alzheimer's Disease Pathophysiology
AD and Amyloid Cascade
AD and Tauopathy
AD and Neurotransmitter Systems
Alzheimer's Disease Etiology
Genetic Factors
Non-Genetic Factors
Alzheimer's Disease Epidemiology
Age of Onset
Incidence, Prevalence and Mortality
Stages and Severity of AD
Comorbidities
Diagnosis and Treatment of Alzheimer's
Diagnosis of Alzheimer's
Companion Imaging Diagnostics for AS
CIDX Technologies for Amyloid Visualization
CIDX Technologies for TAU-NFT Visualization
Comparative Analysis of Tau Tracers in Development
CIDX Technologies: Aβ vs. Tau Imaging Technologies
Concluding Remarks
Pharmaceutical Treatment of AD
Chapter 4 Regulatory Structure
U.S.
Accelerated Approvals
Fast Track Designation
Breakthrough Therapy Designation
Priority Review
Controlled Substances Act
Special Protocol Assessments
New Surveillance and Safety Requirements
Canada
Mexico
Europe
Asia-Pacific
Rest of the World
Reimbursement Landscape
Chapter 5 Market Dynamics
Market Drivers
Use of Biomarkers in Diagnosis and Drug Development
Large Number of Drugs in the Pipeline
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
High Failure Rate in Drug Development
High Cost of Drug Development
Chapter 6 Global Markets for Alzheimer's Disease Therapeutics
Market Overview
Global Market for Alzheimer's Drugs by Mechanism of Action
Acetylcholinesterase Inhibitors (AChEIs)
NMDA Drugs
Global Market for Branded/Generic AD Therapeutics by Type
Global Market for AD Therapeutics by Stage of AD
Chapter 7 Market Breakdown by Region
Global Market for Alzheimer's Drugs by Region
North America
Europe
Asia-Pacific
Rest of the World
Industry Structure
Impact of Generic AD Therapeutics
Chapter 8 Pipeline Analysis
Overview of the Drug Development Process
Phase III
Phase II
Phase I
Trial Sponsors
Chapter 9 Company Profiles
ABBVIE
ACADIA PHARMACEUTICALS INC.
ALEMBIC PHARMACEUTICALS LTD.
ALEXZA PHARMACEUTICALS
ALKERMES PLC
ALLERGAN PLC
APOTEX INC.
ASTRAZENECA PLC
AUROBINDO PHARMA
AVANIR PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
BRISTOL-MYERS SQUIBB CO.
BIOGEN
DAIICHI SANKYO CO., LTD.
DR. REDDY'S LABORATORIES LTD.
ELI LILLY AND CO.
EISAI CO., LTD.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
GEDEON RICHTER PLC
IMMUNOCELLULAR THERAPEUTICS LTD.
JOHNSON & JOHNSON
LANNETT CO., INC.
H. LUNDBECK A/S
LUPIN LTD.
MALLINCKRODT
MERCK & CO.
MYLAN NV
NEXTSOURCE BIOTECHNOLOGY LLC
NOVARTIS AG
OTSUKA HOLDINGS CO., LTD.
PFIZER INC.
SANOFI
SUMITOMO DAINIPPON PHARMA CO., LTD.
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TORRENT PHARMACEUTICALS LTD.
UCB SA
Chapter 10 Appendix: Acronyms

List of Tables
Summary Table : Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 1 : Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Table 2 : Pharmacological Treatment of BPSD of Alzheimer's
Table 3 : Computerized Screening Tests Used in Detecting Cognitive Impairment
Table 4 : Brain Imaging Technologies and Application in the Alzheimer's Context
Table 5 : Global Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 6 : Global Market for Alzheimer's AChEIs Drugs, by Region, Through 2025
Table 7 : Global Market for Alzheimer's NMDA Drugs , by Region, Through 2025
Table 8 : Global Market for Alzheimer's Drugs, by Type, Through 2025
Table 9 : Global Market for AD Therapeutics, by Disease Stage, Through 2025
Table 10 : Global Market for Late Stage/Severe AD Therapeutics, by Region, Through 2025
Table 11 : Global Market for Early/Middle Stage AD Therapeutics, by Region, Through 2025
Table 12 : Global Market for Alzheimer's Drugs, by Region, Through 2025
Table 13 : North American Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 14 : North American Market for Alzheimer's Drugs, by Country, Through 2025
Table 15 : North American Market for Alzheimer's Drugs, by Type, Through 2025
Table 16 : European Market for Alzheimer's Drugs, by Country, Through 2025
Table 17 : European Market for Alzheimer's Drugs, by Type, Through 2025
Table 18 : European Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 19 : Asia-Pacific Market for Alzheimer's Drugs, by Type, Through 2025
Table 20 : Asia-Pacific Market for Alzheimer's Drugs, by Mechanism of Action, Through 2025
Table 21 : Global Ranking of Leading Players in Alzheimer's Disease Drugs
Table 22 : Agents in Phase III of Alzheimer's Disease Drug Development
Table 23 : Agents in Phase II of Alzheimer's Disease Drug Development
Table 24 : Agents in Phase I of Alzheimer's Disease Drug Development
Table 25 : Trial Sponsor for Each Phase of Alzheimer's Disease Drug Development
Table 26 : Acronyms Used in This Report

List of Figures
Summary Figure : Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 1 : Trends in Alzheimer's Patients and Cost of Care for AD in the U.S., 2015-2030
Figure 2 : Pharmaceutical Regulatory Pathways in the U.S. and Europe
Figure 3 : Global Market for Alzheimer's AChEIs Drugs, 2019-2025
Figure 4 : Global Market for Alzheimer's NMDA Drugs, 2019-2025
Figure 5 : Global Market Shares of Alzheimer's Drugs, by Region, 2019
Figure 6 : North American Market for Alzheimer's Drugs, 2019-2025
Figure 7 : European Market for Alzheimer's Drugs, 2019-2025
Figure 8 : Asia-Pacific Market for Alzheimer's Drugs, 2019-2025
Figure 9 : South American Market for Alzheimer's Drugs, 2019-2025
Figure 10 : Middle Eastern and African Market for Alzheimer's Drugs, 2019-2025

Write comment about above report:

Published By: BCC Research

Product Code: BCC Research1251

Related Reports

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Global Alzheimers Disease Therapeutics and Diagnostics Market 2020 by Company, Regions, Type and Application, Forecast to 2025 Market Overview The global Alzheimers Disease Therapeutics and Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.6% in the forecast period of 2020 to 2025 and will expected to r...
2015-2027 Global Alzheimer's Disease Therapeutics and Diagnostics Industry Market Research Report, Segment by Player, Type, Application, Marketing Channel, and Region The worldwide market for Alzheimer's Disease Therapeutics and Diagnostics is estimated to grow at a CAGR of roughly X.X% in the next 8 years, and will reach X.X million US$ in 2027, from X.X million US$ in 2020. The report covers marke...
Global Alzheimers Disease Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026 Alzheimers Disease Therapeutics and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alzheimers Disease Therapeutics and Diagnostics market will be able to gain the upper hand ...
2020-2025 Global and Regional Alzheimer's Disease Therapeutics and Diagnostics Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report HNY Research projects that the Alzheimer's Disease Therapeutics and Diagnostics market size will grow from XXX in 2019 to XXX by 2025, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2...
2020-2025 Global and Regional Alzheimers Disease Therapeutics and Diagnostics Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report HNY Research projects that the Alzheimers Disease Therapeutics and Diagnostics market size will grow from XXX in 2019 to XXX by 2025, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2...
Global and Japan Alzheimer's Disease Therapeutics and Diagnostics Market 2020 by Company, Type and Application, Forecast to 2025 Market Overview The global Alzheimer's Disease Therapeutics and Diagnostics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.9% in the forecast period of 2020 to 2025 and will expected to r...
Global Alzheimer's Disease Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026 Alzheimer's Disease Therapeutics and Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Alzheimer's Disease Therapeutics and Diagnostics market will b...
COVID-19 Impact on Alzheimer's Disease Therapeutics and Diagnostics Market, Global Research Reports 2020-2021 This report covers market size and forecasts of Alzheimer's Disease Therapeutics and Diagnostics, including the following market information: Global Alzheimer's Disease Therapeutics and Diagnostics Market Size, 2019-20...
COVID-19 Outbreak-Global Alzheimer's Disease Therapeutics and Diagnostics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 Alzheimers is a neurodegenerative disorder that mostly occurs with aging and is a leading cause of dementia.The Alzheimer's Disease Therapeutics and Diagnostics market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, w...
Global and Japan Alzheimers Disease Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026 Global Alzheimers Disease Therapeutics and Diagnostics Scope and Market Size Alzheimers Disease Therapeutics and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alzheim...
Global and China Alzheimer's Disease Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026 Global Alzheimer's Disease Therapeutics and Diagnostics Scope and Market Size Alzheimer's Disease Therapeutics and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Alzheim...

We are on:

Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
- Upto 24 hrs - working days
- Upto 48 hrs max - weekends and public holidays

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *